POINT Biopharma Global (PNT) Gets a Buy from JonesTrading

In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on POINT Biopharma Global (PNTResearch Report), with a price target of $18.00. The company’s shares closed yesterday at $5.72.

According to TipRanks, Walsh is an analyst with an average return of -29.6% and a 21.88% success rate. Walsh covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Actinium Pharmaceuticals, and Plus Therapeutics.

Currently, the analyst consensus on POINT Biopharma Global is a Strong Buy with an average price target of $19.57, implying a 242.13% upside from current levels. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a $18.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $10.98 and a one-year low of $4.25. Currently, POINT Biopharma Global has an average volume of 848K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Therapeutics Acquisition Corp is a blank check company.

Read More on PNT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More